Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 19530234)

1.

Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG.

Okamatsu C, London WB, Naranjo A, Hogarty MD, Gastier-Foster JM, Look AT, LaQuaglia M, Maris JM, Cohn SL, Matthay KK, Seeger RC, Saji T, Shimada H.

Pediatr Blood Cancer. 2009 Oct;53(4):563-9. doi: 10.1002/pbc.22106.

2.

Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H.

Cancer. 2001 Nov 15;92(10):2699-708.

PMID:
11745206
3.

International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.

Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, Gerbing RB, Stram DO, Lukens JN, Matthay KK.

Cancer. 2001 Nov 1;92(9):2451-61.

PMID:
11745303
4.

TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.

Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC.

Cancer. 2004 Oct 15;101(8):1873-81.

5.

Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular.

Umehara S, Nakagawa A, Matthay KK, Lukens JN, Seeger RC, Stram DO, Gerbing RB, Shimada H.

Cancer. 2000 Sep 1;89(5):1150-61.

PMID:
10964346
6.

[Correlation between typing of peripheral neuroblastic tumors and prognosis: a clinicopathologic study of 135 cases].

YIN MZ, ZHANG ZD, MA J, SHEN P, CHEN JF, ZHANG HZ.

Zhonghua Bing Li Xue Za Zhi. 2011 Mar;40(3):151-5. Chinese.

PMID:
21575383
7.

High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, El Maani K, Cherkaoui S, Al Zemmouri M, Othmani MB, Zamiati S.

Diagn Mol Pathol. 2013 Jun;22(2):112-8. doi: 10.1097/PDM.0b013e318277448e.

PMID:
23628823
8.

Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular.

Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H.

Cancer. 2003 Nov 15;98(10):2274-81.

9.
10.

Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, Bennani-Othmani M, Sibai H, Itri M, Benchekroun S, Zamiati S.

Diagn Pathol. 2013 Feb 27;8:39. doi: 10.1186/1746-1596-8-39.

11.

The International Neuroblastoma Pathology Classification (the Shimada system).

Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP.

Cancer. 1999 Jul 15;86(2):364-72.

PMID:
10421273
12.

Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.

Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H.

Pediatr Blood Cancer. 2013 Mar;60(3):363-70. doi: 10.1002/pbc.24238. Epub 2012 Jun 28.

13.

Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.

Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B.

Cancer. 1999 Jul 15;86(2):349-63.

PMID:
10421272
14.

The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.

Maitra A, Yashima K, Rathi A, Timmons CF, Rogers BB, Shay JW, Gazdar AF.

Cancer. 1999 Feb 1;85(3):741-9.

PMID:
10091748
15.

[Pathology of peripheral neuroblastic tumors].

Wang L, He LJ, Shimada H.

Zhonghua Bing Li Xue Za Zhi. 2012 Apr;41(4):283-8. doi: 10.3760/cma.j.issn.0529-5807.2012.04.020. Chinese. No abstract available.

PMID:
22800533
16.

[N-myc oncogene amplification in tumors of the sympathetic nervous system: preliminary study of methods and clinico-pathologic correlations].

Dahbiová R, Kodet R, Soukup J, Kavan P, Smelhaus V, Koutecký J.

Cesk Patol. 1997 Aug;33(3):83-8. Czech.

PMID:
9471397
17.

[Clinicopathologic features of peripheral neuroblastic tumors].

Yang BF, Fu LB, He LJ.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):305-10. doi: 10.3760/cma.j.issn.0529-5807.2013.05.004. Chinese.

PMID:
24004586
18.

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.

Veschi V, Petroni M, Bartolazzi A, Altavista P, Dominici C, Capalbo C, Boldrini R, Castellano A, McDowell HP, Pizer B, Frati L, Screpanti I, Gulino A, Giannini G.

Cell Death Dis. 2014 Mar 6;5:e1100. doi: 10.1038/cddis.2014.68.

19.

Conventional versus modified morphologic criteria for ganglioneuroblastoma. A review of cases from the Pediatric Oncology Group.

Joshi VV, Cantor AB, Altshuler G, Cohen LJ, Larkin EW, Shuster JJ, Rao PV, Holbrook CT, Hayes FA, Castleberry RP.

Arch Pathol Lab Med. 1996 Sep;120(9):859-65.

PMID:
9140292
20.

Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.

Banelli B, Bonassi S, Casciano I, Mazzocco K, Di Vinci A, Scaruffi P, Brigati C, Allemanni G, Borzì L, Tonini GP, Romani M.

Int J Cancer. 2010 Feb 1;126(3):656-68. doi: 10.1002/ijc.24768.

PMID:
19626586
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk